PIEZO1 and neoplasm: Additionally, the lack of precision in Piezo1 modulation (e.g., timing and dosage) and tumor heterogeneity further hinder clinical translation; moreover, long-term application of modulators may induce drug resistance, exacerbating these translational challenges.